UBS last night initiated coverage of Beta Technologies (BETA) with a Buy rating and $24 price target The company’s “differentiated” technology is the next “disruptor” in the insulin pump market, the analyst tells investors in a research note. UBS believes Beta is well positioned for double-digit growth and continued margin expansion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BETA:
- Surf Air Mobility partners with Hawaii Department of Transportation, Beta Technologies
- Early Leader in Electric Aviation: Full-Stack Strategy and Ecosystem Strength Justify Buy Rating and Premium Valuation on BETA Technologies
- JOBY, ACHR: What’s Driving the Jump in These eVTOL Stocks
- Beta Technologies falls -6.2%
- Beta Technologies collaborates with U.S. DOT over Advanced Air Mobility